慢性肾脏病血脂异常表型与冠心病风险相关
本研究纳入6612例基线无冠心病的多种族动脉粥样硬化研究个体,用主成分分析刻画慢性肾脏病(CKD)血脂异常表型。CKD定义为eGFR 15至<60 mL/min/1.73 m2(3-4期)。CKD组冠心病发生率12%,高于eGFR≥60组的5%(P<0.001);以甘油三酯、富甘油三酯脂蛋白、小LDL颗粒升高和HDL颗粒降低为主的表型在CKD中更常见,且与冠心病关联更强。
要点
- CKD(3-4期)患者冠心病发生率为12%,显著高于eGFR≥60者的5%。
- 以富甘油三酯脂蛋白和小LDL升高、HDL降低为主的表型在CKD中更常见。
- 该血脂表型与冠心病关联在CKD中更强(交互P=0.05)。
核心结论
- 在主要为3期CKD的个体中,以富甘油三酯脂蛋白及其他密切相关脂蛋白为主的血脂表型与冠心病风险强烈相关。
研究设计与样本
- 多民族动脉粥样硬化研究中的6612名基线无冠心病个体。
- CKD定义为eGFR 15至<60 mL/min/1.73 m2(3-4期)。
- 采用主成分分析刻画CKD血脂异常表型。
- 冠心病定义为新发心肌梗死、心绞痛后血运重建、复苏的心脏骤停或冠心病死亡。
主要发现
- CKD组发生冠心病72例(12%),eGFR≥60组303例(5%),差异P<0.001。
- 主成分1(PC1)表型在CKD中更常见(P<0.001),表现为甘油三酯、富甘油三酯脂蛋白(VLDL颗粒)、小LDL颗粒升高和HDL颗粒降低。
- PC1每增加1个标准差,eGFR≥60组冠心病调整HR为1.13(95%CI 1.00至1.27;P=0.05),CKD组为1.51(95%CI 1.17至1.94;P<0.001),交互P=0.05。
临床怎么用
- 对CKD(3-4期)患者应关注以富甘油三酯脂蛋白和小LDL升高、HDL降低为主的血脂表型,其与冠心病风险关联更强。
局限性
- 未来需研究干预该表型组分能否降低CKD患者的冠心病负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study sought to characterise the main dyslipidaemic phenotypes present in chronic kidney disease (CKD) and their association with coronary heart disease (CHD) risk. METHODS: Analyses included 6612 individuals in the multiethnic study of atherosclerosis free of CHD at baseline. CKD was defined as an estimated glomerular filtration rate (eGFR) of 15 to <60 mL/min/1.73 m2 (stages 3-4). Principal component analyses were used to characterise the main dyslipidaemic phenotypes of CKD accounting for the correlation among different lipoproteins and lipoprotein particles. CHD was defined as incident myocardial infarction, angina followed by revascularisation, resuscitated cardiac arrest or CHD death. RESULTS: CHD developed in 303 individuals (5%) with eGFR ≥60 and in 72 individuals (12%) with CKD (p for difference <0.001). A dyslipidaemic phenotype (principal component 1 (PC1)) consisting of elevations in triglycerides, triglyceride-rich lipoproteins (VLDL particles), small LDL particles and reductions in HDL particles, was more common in those with CKD, compared with those without CKD (p for difference <0.001). This phenotype was also more strongly associated with CHD in those with CKD: adjusted HRs (95% CIs) per SD increase in PC1 1.13 (95% CI 1.00 to 1.27; P=0.05) and 1.51 (95% CI 1.17 to 1.94; P<0.001) in eGFR ≥60 and CKD, respectively (P for interaction=0.05). CONCLUSION: In individuals with mainly stage 3 CKD, a dominant lipid phenotype consisting of triglyceride-rich lipoproteins and other closely correlated lipoproteins is strongly associated with CHD risk. Future studies should investigate whether modification of the components of this phenotype leads to a reduction in the CHD burden in individuals with CKD.
引用
- Lamprea-Montealegre JA, McClelland RL, Grams M, et al. Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. Heart. 2018. PMID: 29472290. doi:10.1136/heartjnl-2017-312794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。